Reducing delayed intensification therapy in childhood ALL
Mené sur 521 patients atteints d'une leucémie lymphoblastique aiguë à faible risque (âge compris entre 1 et 25 ans), cet essai randomisé évalue, du point de vue de la durée de survie sans événement, l'efficacité d'une réduction de l'intensité du traitement (durée médiane de suivi : 57 mois)
Optimum use of chemotherapy, precise risk classification, and improved supportive care have increased the proportion of children with acute lymphoblastic leukaemia (ALL) who survive to 5 years to 90% or higher in several contemporary trials.This achievement has shifted research emphasis to the reduction of toxic effects, especially in patients with a low risk of relapse, while preserving gains in long-term survival. The Medical Research Council's UKALL 2003 trial, published in The Lancet Oncology,4 provides compelling evidence for the efficacy of this approach...
The Lancet Oncology , commentaire en libre accès, 2012